SPTX (Seaport Therapeutics) Total Liabilities: $341.55 Mil (As of Dec. 2025)


SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $21.43
! 1 Warning Sign
View Full Analysis

What is Seaport Therapeutics Total Liabilities?

Seaport Therapeutics SPTX +10.37% 11 Total Liabilities is $341.55 Mil as of Dec. 2025. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 1 warning sign investors should review.

Seaport Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 was $341.55 Mil.

Seaport Therapeutics's quarterly Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($340.63 Mil) and increased from Dec. 2024 ($340.63 Mil) to Dec. 2025 ($341.55 Mil).

Seaport Therapeutics's annual Total Liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($340.63 Mil) and increased from Dec. 2024 ($340.63 Mil) to Dec. 2025 ($341.55 Mil).

Seaport Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Seaport Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seaport Therapeutics Total Liabilities Chart

Seaport Therapeutics Annual Data
Trend Dec24 Dec25
Total Liabilities
340.63 341.55

Seaport Therapeutics Semi-Annual Data
Dec24 Dec25
Total Liabilities 340.63 341.55
SPTX
11GF Score
Seaport Therapeutics Inc SPTX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seaport Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Seaport Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.782+(3.444+325.328
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=341.55

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=249.009--92.545
=341.55

Seaport Therapeutics's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=12.782+(3.444+325.328
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=341.55

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=249.009--92.545
=341.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $341.55 Mil mean?
Seaport Therapeutics (SPTX) has a Total Liabilities of $341.55 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Seaport Therapeutics and its competitors.
Is Seaport Therapeutics' Total Liabilities too high?
Seaport Therapeutics' current Total Liabilities is $341.55 Mil. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' Total Liabilities compare to LXRX and DRTS?
Seaport Therapeutics' Total Liabilities of $341.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Seaport Therapeutics and its competitors. Seaport Therapeutics's current Total Liabilities is $341.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current Total Liabilities of $341.55 Mil. The current Total Liabilities is $341.55 Mil. Seaport Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current Total Liabilities is $341.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.43
Price